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is increased rate of metabolism of a drug after it has
been given; the drug has increased the activity of the
gene that controls its metabolizing enzyme. Another
example: an alcoholic is a person whose original
consumption of alcohol has affected a gene in the brain
that affects the wish to drink more of it.
Since innumerable internal and environmental factors
may affect gene expression, a person's set of genes is
never constant but always more or less changing. This
makes it impossible to exactly predict the activities of a
person's genes. However, not all genes change their
expression over a given time. There must be a
likelihood that a set of genes studied a week apart is
more similar than when studied a month or a year apart.
We do not know whether a set of genes remains more
constant over time within person A than within person
B. Thus, at the present time, dealing with gene
expression is usually a matter of probability, and
perhaps never or rarely of certainty. Consequently,
when dealing with gene expression and with future drug
responses, one is dealing with matters of probability.
By the same token, we can never precisely predict the
effect of a drug on a person, although it often remains
identical over reasonable periods; prediction of the
effect of a drug is a matter of probability, and thus is
'personalized medicine'.
In short, there have been some steps made towards
personalized medicine, but it will never be a reliable
entity; it is an entity of probability. 
FEATURE REVIEW
Medical practice has never been pure science; every
physician automatically considers the patient's
personality or circumstances when deciding to help him
or her. Thus, to some extent, medical practice can be
said to have always represented personal medicine. The
current interest in, and emphasis on, personal medicine
is based on the fact that regular drug treatment has
sometimes very irregular responses, which cannot be
explained by the patient's look and appearance; e.g. a
generally safe drug may kill a patient, or a good drug
may be ineffective in some patients. Such problems
have led to the discovery that irregular drug responses
in different people may be caused by differences
between their genes, thereby creating the science of
'Pharmacogenetics'.
Pharmacogenetics has taught us that variations in
gene structure may affect their dependent proteins,
which may be pharmacologically important (e.g. drug-
metabolizing enzymes, or the receptors whose
occupation determines the drug's effect). By assessing a
patient's crucial gene, one can often determine which
drug, or which drug dose, is appropriate for that patient.
Utilization of such search may rightly be called
'personalized medicine'. This is now sometimes done in
a clinic, but so far, not often in medical practice.
However, it turned out that such pharmacogenetic
procedures could explain only a small proportion of
abnormal drug responses. Thus, many investigators
have looked for further explanations and for additional
tests, as demonstrated by the 450 publications
mentioned above.
The most important explanation for the occurrence of
unexpected drug responses not-explainable by
environmental factors or by classical pharmacogenetics
lies in the fact that gene expression is variable. Variable
gene expression means that the number of a given kind
of gene may change, thereby affecting the gene's
function. Gene expression can be altered by many
internal and environmental factors. A classical example
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